Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK104 plus chemotherapy for unresectable stage IIIB/IIIC PD-L1-high non-small-cell lung cancer
ChiCTR2300077568Phase 2Not yet recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Nov 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab in non-small cell lung cancer (NSCLC), sponsored by Shandong Cancer Hospital. Primary endpoint: 12-month progression-free survival rate. Planned start Nov 2023; status: not yet recruiting.
02
Drugs
cadonilimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2300077568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300077568.